A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
Phase 1
18–55
8 sites in AL, CA, DC +5
About this study
This Phase 1 study is focused on people with hiv. The primary outcome being measured is Part A: AUC of PGDM1400LS.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
infusion, subcutaneous
Primary: Part A: AUC of PGDM1400LS, Part A: AUC of VRC07-523LS, Part A: Area Under the Concentration-Time Curve (AUC) of ePGT121v1-LS, Part A: Area Under the Magnitude-Breadth Curve (AUC-MB), Part A: Clearance (CL) of ePGT121v1-LS, Part A: Cmax of PGDM1400LS, Part A: Cmax of VRC07-523LS, Part A: Maximum Observed Concentration (Cmax) of ePGT121v1-LS
Secondary: Area Under the Magnitude-Breadth Curve (AUC-MB), Correlation Between Serum/Plasma Concentration and AUC-MB of Serum Neutralization Across the Virus Panel, Population pharmacokinetic (PopPK) modeling of monoclonal antibody (mAb) concentration-time data
Immune, Infectious